Industry still cares about switching
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Industry was “absolutely interested in switches”, insisted Dirk Ossenberg-Engels, head of Bayer Consumer Health’s Europe South, Central Eastern Europe and Middle East business unit, after the sector’s commitment to prescription-to-OTC reclassification was challenged by Christa Wirthumer-Hoche, chair of the management board of the European Medicines Agency (EMA).